(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...
Morning Overview on MSN
What to know about viral peptide health claims and the risks
Unapproved peptide drugs have surged into mainstream wellness culture, promoted by influencers, fitness coaches, and ...
Morning Overview on MSN
The biggest GLP-1 drug mistake, and how to avoid it
The FDA has spent much of 2025 issuing warnings about a single, recurring problem with GLP-1 weight loss drugs: patients and ...
2d
Diabetes advocates cross their fingers as a bipartisan bill revives efforts to lower insulin costs
A bipartisan group of senators is aiming to relieve that cost burden with the INSULIN Act , a bill to cap the cost of the ...
Austin, March 20, 2026 (GLOBE NEWSWIRE)-- According to SNS Insider, The Insulin Delivery Devices Market size was valued at USD 19.13 billion in 2025 and is expected to reach USD 41.00 billion by 2035, ...
“Insulin injections remain a daily burden for many patients,” said Shingo Ito, an associate professor at Kumamoto University ...
The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...
Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly ...
Novo Nordisk announced today that it received FDA approval for Awiqli, the first and only once-weekly, long-acting basal ...
Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in ...
Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results